Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples